THE EFFECT OF THE TIME AND REGULARITY OF ADMINISTRATION OF IMATINIBMESYLATE (GLIVEK) ON SURVIVAL RATE
- 作者: Kaplanov K.D.1, Klitochenko TY.1, Ovsyannikova EG1, Kalashnikova OB1, Tregubova LS1, Matveeva IV1, Shipaeva AL1, Gemdzhyan EG1, Kaplanov KD1, Klitochenko TY1, Ovsyannikova EG1, Kalashnikova OB1, Tregubova LS1, Matveeva IV1, Shipaeva AL1, Gemdgyan EG1
-
隶属关系:
- 期: 卷 7, 编号 3 (2010)
- 页面: 19-25
- 栏目: Articles
- URL: https://journals.eco-vector.com/1994-9480/article/view/118151
- ID: 118151
如何引用文章
全文:
详细
the chronic myeloid leukemia, were processed and analyzed.
126 patients from the register were not treated with imatinib, and 103 patients started receiving imatinib at different
times from the moment of diagnosis.
We revealed a dependence of the length of imatinib therapy on the survival rate. Early onset of treatment (up to 4
months from the moment of diagnosis) has a reliable influence on uneventful survival and determines a tendency for overall
survival improvement
作者简介
Kamil' Kaplanov
Email: kamilos@mail.ru
T Klitochenko
E Ovsyannikova
O Kalashnikova
L Tregubova
I Matveeva
A Shipaeva
E Gemdzhyan
K Kaplanov
T Klitochenko
E Ovsyannikova
O Kalashnikova
L Tregubova
I Matveeva
A Shipaeva
E Gemdgyan
参考
- Волкова М. А. // Эффективная фармакотерапия в онкологии, гематологии и радиологии. - 2009. - № 2. - С. 3.
- Baccarani M., Salgio G.,Goldman J., et al. // Blood. - 2006. - № 108. - Р. 1809-1820.
- Daley G., Van Etten R., Baltimore D. // Science. - 1990. - Vol. 247. - Р. 824.
- de Lavallade H., Apperley J. F., Khorashad J. S., et al. // J. Clin. Oncol. - 2008. - № 26. - Р. 3358-3363.
- Druker B., Guilhot F., O'Brien S., et al. // N. Engl. J. Med. - 2006. - № 355. - Р. 2408-2417.
- Guilhot F., Chastang C., Michallet M., et al. // N. Engl. J. Med. - 1997. - № 337. - Р. 223.
- Hehlmann R., Heimpel H., Hasford J., et al. // Blood. - 1993. - № 82. - Р. 398.
- Katarjian H., Sawyers C., Hochhaus A., et al. // N. Engl. J. Med. - 2002. - Vol. 346. - Р. 645-652.